Flare

COMPASS Pathways appoints Daphne Karydas to its Board of Directors

Retrieved on: 
Monday, September 18, 2023
JPMorgan Chase, BS, Depression, Goldman, Chronic kidney disease, Senior, Health, Goldman Sachs, Biotechnology, Allergan, Cancer, MBA, Infection, COMPASS, Merck & Co., AstraZeneca, MS, Massachusetts Institute of Technology, Hypertension, Anorexia nervosa, Aldosterone, Acquisition, Post-traumatic stress disorder, AbbVie, Flare, Patient, Chemical engineering, Corporation, Factorization of polynomials, Harvard Business School, Merck, CMPS, Treasurer, Therapy, Mental health, Pharmaceutical industry, Nursing

LONDON, Sept. 18, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the appointment of Daphne Karydas to its Board of Directors, effective September 18, 2023.

Key Points: 
  • LONDON, Sept. 18, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the appointment of Daphne Karydas to its Board of Directors, effective September 18, 2023.
  • Ms. Karydas is President and Chief Financial Officer at Flare Therapeutics Inc., a privately held biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases.
  • “Daphne is an ideal match for the COMPASS Pathways Board of Directors as we progress our phase 3 COMP360 psilocybin program in treatment-resistant depression and our phase 2 programs in anorexia nervosa and post-traumatic stress disorder,” said George Goldsmith, Chairman of the COMPASS Pathways Board of Directors.
  • We are delighted to welcome her.”
    “I am excited to join the COMPASS board as the company advances its pioneering COMP360 psilocybin program,” said Ms. Karydas.

Inbound Health Secures $30 Million in Funding Led by HealthQuest Capital to Accelerate Growth of At-Home Advanced Care Programs

Retrieved on: 
Wednesday, September 20, 2023
Infection, Health, Growth, Partnership, Hospital, McKesson Corporation, Delirium, Patient, Flare, Economics, Nursing

MINNEAPOLIS, Sept. 20, 2023 /PRNewswire-PRWeb/ -- Inbound Health, a company that enables health systems to offer acute and post-acute care in the home, announced today the successful close of a $30 million Series B funding round. This investment is led by HealthQuest Capital with participation from existing investors Flare Capital Partners and McKesson Ventures.

Key Points: 
  • This investment is led by HealthQuest Capital with participation from existing investors Flare Capital Partners and McKesson Ventures.
  • Inbound Health's Series B financing arrives at a time when health systems are increasingly leveraging the home as a site of care.
  • The programs that Inbound Health powers are demonstrating key clinical, operational and financial benefits for its health system partners.
  • "We are excited to embark on this next phase of growth with the strong backing of our investors, led by HealthQuest Capital," said Dave Kerwar, CEO of Inbound Health.

CARFAX DATA: AUTUMN IS THE MOST DANGEROUS SEASON FOR AUTO ACCIDENT DAMAGE IN U.S.

Retrieved on: 
Monday, September 18, 2023
Pack, Maintenance, Flare, Travel, Accident, Daylight saving time, Season, Table tennis rubber, Ice, Data, Water, Tire, Windex, Crash, Road, Tire manufacturing

CENTREVILLE, Va., Sept. 18, 2023 /PRNewswire/ -- Tens of millions of U.S. drivers are heading this week directly into Danger Season – the time when auto crashes occur most often where they live, CARFAX data shows. Although many might assume that Winter is the most accident-prone season, more than 72% of U.S. drivers – roughly 170 million – live in states where Fall is the peak season for accident damage.

Key Points: 
  • Although many might assume that Winter is the most accident-prone season, more than 72% of U.S. drivers – roughly 170 million – live in states where Fall is the peak season for accident damage.
  • "CARFAX has the most accident and damage information, and sometimes that data can be surprising."
  • Braking on wet leaves can make a car travel more than twice as far as braking on a dry road.
  • "CARFAX has the most accident and damage information, and sometimes that data can be surprising," said Faisal Hasan, General Manager for Data at CARFAX.

Mineralys Therapeutics Expands its Board of Directors with Appointments of Glenn Sblendorio and Daphne Karydas

Retrieved on: 
Thursday, September 14, 2023
OSI Pharmaceuticals, Chronic kidney disease, Biotechnology, Allergan, Finance, Amicus Therapeutics, Fairleigh Dickinson University, Strategic management, Hypertension, Sequah Medicine Company, Massachusetts Institute of Technology, Patient, Flare, Chemical engineering, Pace University, Harvard Business School, Intercept Pharmaceuticals, Astellas Pharma, Growth, Therapy, CKD, Daphne, Pharmaceutical industry, Management

In addition, Mineralys announced that Takeshi Takahashi of Catalys Pacific has stepped down from the Board, effective September 12, 2023.

Key Points: 
  • In addition, Mineralys announced that Takeshi Takahashi of Catalys Pacific has stepped down from the Board, effective September 12, 2023.
  • “We are excited to have Daphne and Glenn join our Board and support Mineralys' efforts to develop innovative medicines aimed to improve the lives of patients with cardiorenal disorders.
  • Ms. Karydas has previously served on the boards of directors at Elicio Therapeutics, LogicBio Therapeutics, Inc., and Eucrates Biomedical Acquisition Corp. Ms. Karydas received a B.A.
  • Mr. Sblendorio also serves as a member of the board of directors of Intercept Pharmaceuticals, Inc. and as a member of the board of directors of Amicus Therapeutics, Inc. Mr. Sblendorio received his B.B.A.

Arcutis Submits Roflumilast Cream 0.15% Supplemental New Drug Application to the FDA for the Treatment of Atopic Dermatitis in Adults and Children Ages 6 Years and Older

Retrieved on: 
Tuesday, September 12, 2023
PDE4, Flare, Disease, Irritant, Prevalence, Week, Oregon Health & Science University, Ethanol, Dermatitis, Parent, George Washington University School of Engineering and Applied Science, New Drug Application, George Washington University School of Medicine & Health Sciences, Propylene glycol, Skin, Atopic dermatitis, FAAD, Excipient, Oregon Health Plan, IGA, MCR, Shanda, MD, Patient, Risk, SUNY Downstate Health Sciences University, Outline of health sciences, AD, FDA, MPH, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Safety, Success, Vaccine, Pharmaceutical industry, Dermatology, Doctor of Philosophy

In clinical studies, once-daily roflumilast cream provided rapid clearance of the disease.

Key Points: 
  • In clinical studies, once-daily roflumilast cream provided rapid clearance of the disease.
  • Roflumilast cream is uniquely formulated with HydroARQ Technology™ as a non-greasy emollient cream that absorbs quickly and does not disrupt the skin barrier.
  • “Topical roflumilast cream was intentionally formulated with the atopic dermatitis patient in mind, and does not contain excipients that disrupt skin-barrier integrity or are common contact allergens.
  • I would like to thank the team at Arcutis for their incredible hard work and dedication,” added Watanabe.

HydroGraph and EMP Shield to Create Next-Gen EMI Shielding

Retrieved on: 
Monday, September 11, 2023
CHIPS, Science, Flare, CSE, Electronics, Telecommunications, Smartphone, Bulgarian–American Joint Military Facilities, Secretary of State of Kansas, NDA, EMI, EMP, Hydrograph, Lightning, Corrosion, HG, Pharmaceutical industry

Under this collaboration, the Company and EMP Shield are developing advanced electromagnetic interference (EMI) shielding using HydroGraph’s high-purity graphene.

Key Points: 
  • Under this collaboration, the Company and EMP Shield are developing advanced electromagnetic interference (EMI) shielding using HydroGraph’s high-purity graphene.
  • HydroGraph and EMP Shield are working together to develop coatings and insulated barriers to protect electronic devices by blocking unwanted disruptions or transmission of electronic data.
  • “It is an exciting opportunity to be the first company to utilize graphene-enhanced EMI coatings,” said Tim Carty, EMP Shield’s founder and lead engineer.
  • “EMI shielding is just one of the many critical uses we are discovering for graphene,” said Stuart Jara, HydroGraph’s CEO.

Estes Energetics Restarts Shipment of GOEX Black Powder

Retrieved on: 
Friday, September 8, 2023
Estes Industries, Flare, Partnership, DuPont, Energetics, DPA, United States Army, United States Department of the Army, Hunting, Safety, Explosive

As the only remaining commercial black powder factory in the United States, this plant produces GOEX and Olde Eynsford brands of black powder, which are highly regarded by competitive and recreational shooters, re-enactors, muzzleloading hunters, and fireworks manufacturers.

Key Points: 
  • As the only remaining commercial black powder factory in the United States, this plant produces GOEX and Olde Eynsford brands of black powder, which are highly regarded by competitive and recreational shooters, re-enactors, muzzleloading hunters, and fireworks manufacturers.
  • GOEX black powder also propels the model rocket motors of sister company Estes Industries, the leading model rocket brand, and supports the needs of the U.S. military.
  • GOEX traces its roots back to 1802, when DuPont opened the country’s first black powder plant in Delaware.
  • Estes Energetics is continuing this 220-year legacy of high-quality American-made black powder, bringing innovation and full-spectrum engineering capability to fortify safety and quality.

Shields Health Solutions Consistently Demonstrates Superior Clinical Outcomes

Retrieved on: 
Tuesday, September 12, 2023
AIDS, Health, Physical Therapy, Other Health, Managed Care, General Health, Pharmaceutical, Insurance, Flare, RA, Doctor of Pharmacy, HIV, Pharmacy, Disability, Research, Multiple sclerosis, Hepatitis C, MS, CDC, NASP, Literature, Hospital, Specialty pharmacy, Patient, ARR, Diagnosis, National Association, Pharmaceutical industry, Health insurance, Nursing, Shield

Shields Health Solutions (Shields), the premier specialty pharmacy accelerator in the country, recently published its latest patient outcomes in key disease states such as hepatitis C, HIV, rheumatoid arthritis (RA), and multiple sclerosis (MS).

Key Points: 
  • Shields Health Solutions (Shields), the premier specialty pharmacy accelerator in the country, recently published its latest patient outcomes in key disease states such as hepatitis C, HIV, rheumatoid arthritis (RA), and multiple sclerosis (MS).
  • Through collaboration with its health system partners nationwide, these industry-leading patient outcomes further illustrate the effectiveness of Shields’ integrated care model.
  • “We are thrilled to reinforce our reputation as the nation’s leading specialty pharmacy partner through our exceptional outcomes in various complex disease states,” said Brian S. Smith, PharmD, Chief Pharmacy Officer at Shields.
  • Furthermore, 93% of Shields patients reported their condition improved or stabilized since receiving care through the network of integrated health system specialty pharmacies.

Maxon One Fall Release Includes New Features and Massive Performance Improvements

Retrieved on: 
Wednesday, September 13, 2023
Universe, Giant, Umbrella, Lighting control console, Stroke, Explosion, Projection, Collection, Node, Magic bullet, UPR Info, Software, Metal, Vertex, 3D, Language, BAD, Nickel, Virginian, VFX, Artifact, Workflow, Red, Design, Urban Ring Project (MBTA), Thought, Creativity, Gold, Note, Flare, Schmutz, Combustion, Cupressus sempervirens, Fitzwilliam Museum, Work, Central processing unit, Cinema 4D, Movement, Plant, Distortion, Red giant, Camera, 3D printing, Video game, Cryptocurrency, Telescopic sight, Redshift, Pyro, Parent, Blender, Capsule, Effect

BAD HOMBURG, Germany, Sept. 13, 2023 /PRNewswire-PRWeb/ -- Maxon, developers of professional software solutions for editors, filmmakers, motion designers, visual effects artists and creators of all types, is thrilled to announce the highly anticipated September release with updates for nearly all Maxon products. Cinema 4D 2024 is better than ever - with massive performance improvements in interactive playback, enhancements to Rigid Body simulations and a more "art-directable" Pyro workflow. With Trapcode 2024, artists can now create realistic thermal dynamics with the new Combustion feature and create particle tracks with Stroke from Parent. VFX 2024 opens up a new dimension in lighting control and includes several enhancements to the popular Real Lens Flares. With Magic Bullet 2024, color correction is easier than ever - plus a host of new presets give artists more creative freedom. Universe 2024 also sees numerous workflow improvements and offers new presets. Redshift offers more creative freedom when using the MatCap and Distorter shaders as well as performance improvements on multi-core CPUs. As a special treat for Maxon One subscribers comes our most comprehensive drop of Maxon Capsules to this date, including a new spline modifier by Rocket Lasso, Redshift Metal and Car Paint materials, as well as 3D models ready to use for interior and exterior visualization.

Key Points: 
  • Cinema 4D 2024 is better than ever - with massive performance improvements in interactive playback, enhancements to Rigid Body simulations and a more "art-directable" Pyro workflow.
  • VFX 2024 opens up a new dimension in lighting control and includes several enhancements to the popular Real Lens Flares.
  • Redshift offers more creative freedom when using the MatCap and Distorter shaders as well as performance improvements on multi-core CPUs.
  • Cinema 4D 2024 is better than ever - with massive performance improvements in interactive playback, enhancements to Rigid Body simulations and a more "art-directable" Pyro workflow.

NBA Dunk Contest Winner Glenn Robinson III Will Teach You "HOW TO DUNK" With New Online Program Available Now!

Retrieved on: 
Tuesday, September 12, 2023
Indiana Pacers, NCAA, Flare, Seven Years' War, Slam Dunk Contest, History of the Indiana Pacers, Golden, Detroit Pistons, Michigan Wolverines, NBA, LOS, Minnesota Timberwolves, Golden State Warriors, 2013–14 Michigan Wolverines men's basketball team, All Star Weekend, Sport, Sacramento Kings

LOS ANGELES, Sept. 12, 2023 /PRNewswire-PRWeb/ -- Today, seven-year NBA veteran and dunk artisan, Glenn Robinson III a.k.a. "GR3" officially launches his brand-new program, "How To Dunk." It proudly lives up to its title with a course personally taught by the NBA Slam Dunk Contest Champion. He demystifies everyone's favorite two-point trick with a groundbreaking step-by-step path to the rim. You could think of it as the "Rosetta Stone" of the backboard.

Key Points: 
  • Learn "How To Dunk" with NBA Veteran and Dunk Contest Winner Glenn "GR3" Robinson III!
  • LOS ANGELES, Sept. 12, 2023 /PRNewswire-PRWeb/ -- Today, seven-year NBA veteran and dunk artisan, Glenn Robinson III a.k.a.
  • It proudly lives up to its title with a course personally taught by the NBA Slam Dunk Contest Champion.
  • It proudly lives up to its title with a course personally taught by the NBA Slam Dunk Contest Champion.